GB1183403A - Antitussive Medicament with Prolonged Effect - Google Patents

Antitussive Medicament with Prolonged Effect

Info

Publication number
GB1183403A
GB1183403A GB9794/67A GB979467A GB1183403A GB 1183403 A GB1183403 A GB 1183403A GB 9794/67 A GB9794/67 A GB 9794/67A GB 979467 A GB979467 A GB 979467A GB 1183403 A GB1183403 A GB 1183403A
Authority
GB
United Kingdom
Prior art keywords
antitussive
base
weight
medicament
noscapine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB9794/67A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mead Johnson and Co LLC
Original Assignee
Mead Johnson and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mead Johnson and Co LLC filed Critical Mead Johnson and Co LLC
Publication of GB1183403A publication Critical patent/GB1183403A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0036—Galactans; Derivatives thereof
    • C08B37/0042—Carragenan or carragen, i.e. D-galactose and 3,6-anhydro-D-galactose, both partially sulfated, e.g. from red algae Chondrus crispus or Gigantia stellata; kappa-Carragenan; iota-Carragenan; lambda-Carragenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,183,403. Antitussive medicament. MEAD JOHNSON & CO. 1 March, 1967 [18 March, 1966], No. 9794/67. Heading A5B. [Also in Division C3] Antitussive compositions having prolonged effect contain in each dosage unit an effective amount of at least one of the complexes of a sulphated polysaccharide selected from the group of carrageenans and an antitussive base selected from the opium alkaloids and synthetic derivatives and analogues thereof, said complex being formed by contacting a watersoluble acid addition salt of said base with an aqueous solution containing from 1 to 10 parts by weight of sulphated polysaccharide per part by weight of said base at a temperature of 40-60‹C. The antitussive base may be morphine, codeine, noscapine, pholcodine, ethylmorphine, diacetylmorphine, dihydromorphine, dihydrocodeinone or dextromethorphan, the complex containing 9 to 50% by weight of the base. The compositions may be administered orally in the form of liquids, compressed tablets and gelatin capsules. A preferred composition contains carrageenan complexes of codeine and noscapine.
GB9794/67A 1966-03-18 1967-03-01 Antitussive Medicament with Prolonged Effect Expired GB1183403A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR54024A FR5227M (en) 1966-03-18 1966-03-18

Publications (1)

Publication Number Publication Date
GB1183403A true GB1183403A (en) 1970-03-04

Family

ID=8604122

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9794/67A Expired GB1183403A (en) 1966-03-18 1967-03-01 Antitussive Medicament with Prolonged Effect

Country Status (6)

Country Link
AT (1) AT279802B (en)
BE (1) BE695604A (en)
DK (1) DK115144B (en)
FR (1) FR5227M (en)
GB (1) GB1183403A (en)
NL (1) NL6704037A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091409A1 (en) * 1982-03-12 1983-10-12 KabiVitrum AB Pharmaceutical compositions containing carrageen
EP0233932A1 (en) * 1985-08-16 1987-09-02 New York University Anticonvulsant compositions and method
US4898860A (en) * 1985-08-16 1990-02-06 New York University Anticonvulsant composition and method
FR2640137A1 (en) * 1988-12-08 1990-06-15 Texinfine Sa SYSTEMS CONVEYING LIPOPHILIC ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING SAME
EP0454044A2 (en) * 1990-04-25 1991-10-30 Hoechst Aktiengesellschaft Pharmacological product containing polyelectrolyte complexes in microparticulate form and at least one substance
WO1999021586A2 (en) * 1997-10-29 1999-05-06 Eurand International S.P.A. Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions
FR2906687A1 (en) * 2006-10-10 2008-04-11 Pierre Calleja Substrate for conservation and distribution of an active ingredient for aquatic animals, comprises an active ingredient, a hydrocolloid substance to inflate in contact with water, a palatable base, and a compressed metal base
US7939103B2 (en) 2004-03-19 2011-05-10 Capsulution Pharma Ag Method for producing core-shell (CS) particles and microcapsules using porous templates, CS particles and microcapsules, and the use thereof
US8092836B2 (en) 1998-03-19 2012-01-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU565487B2 (en) * 1983-09-16 1987-09-17 Fisons Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
US4762709A (en) * 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091409A1 (en) * 1982-03-12 1983-10-12 KabiVitrum AB Pharmaceutical compositions containing carrageen
US4693997A (en) * 1982-03-12 1987-09-15 Kabivitrum Ab Novel pharmaceutical composition
EP0233932A1 (en) * 1985-08-16 1987-09-02 New York University Anticonvulsant compositions and method
EP0233932A4 (en) * 1985-08-16 1988-04-26 Univ New York Anticonvulsant compositions and method.
US4898860A (en) * 1985-08-16 1990-02-06 New York University Anticonvulsant composition and method
FR2640137A1 (en) * 1988-12-08 1990-06-15 Texinfine Sa SYSTEMS CONVEYING LIPOPHILIC ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING SAME
US5700459A (en) * 1990-04-25 1997-12-23 Hoechst Aktiengesellschaft Pharmacological composition containing polyelectrolyte complexes in microparticulate form and at least one active agent
EP0454044A3 (en) * 1990-04-25 1993-01-13 Hoechst Aktiengesellschaft Pharmacological product containing polyelectrolyte complexes in microparticulate form and at least one substance
EP0454044A2 (en) * 1990-04-25 1991-10-30 Hoechst Aktiengesellschaft Pharmacological product containing polyelectrolyte complexes in microparticulate form and at least one substance
WO1999021586A2 (en) * 1997-10-29 1999-05-06 Eurand International S.P.A. Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions
WO1999021586A3 (en) * 1997-10-29 1999-07-08 Eurand Int Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions
US6355272B1 (en) 1997-10-29 2002-03-12 Eurand International S.P.A. Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions
US8092836B2 (en) 1998-03-19 2012-01-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US8168226B2 (en) 1998-03-19 2012-05-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US7939103B2 (en) 2004-03-19 2011-05-10 Capsulution Pharma Ag Method for producing core-shell (CS) particles and microcapsules using porous templates, CS particles and microcapsules, and the use thereof
FR2906687A1 (en) * 2006-10-10 2008-04-11 Pierre Calleja Substrate for conservation and distribution of an active ingredient for aquatic animals, comprises an active ingredient, a hydrocolloid substance to inflate in contact with water, a palatable base, and a compressed metal base

Also Published As

Publication number Publication date
DK115144B (en) 1969-09-08
AT279802B (en) 1970-03-25
BE695604A (en) 1967-09-18
NL6704037A (en) 1967-09-19
FR5227M (en) 1967-08-14

Similar Documents

Publication Publication Date Title
GB1390772A (en) Oral narcotic composition
GB1183403A (en) Antitussive Medicament with Prolonged Effect
IE771403L (en) Injection solutions
IE781163L (en) Sustained release of veterinary medicaments
GB1517480A (en) Opiate analgesic formulation with a low potential for abuse
GB1353815A (en) Analgetic composition
CA2190943A1 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
HK19481A (en) 3,4-dihydrocarbostyril derivatives,their preparation,and pharmaceutical compositions thereof
GB1378348A (en) Orally administered drug composition for therapy in the treatment of narcotic drug addiction
ES320356A1 (en) Improvements in or relating to pharmaceutical pastilles
US3456051A (en) Soft gelatin sheet for soft gelatin capsule
Hartmann Amitriptyline and imipramine: effects on human sleep.
IL50355A (en) N-tetrahydrofurfuryl noroxymorphone derivatives,their preparation and pharmaceutical compositions containing them
GB1453234A (en) Liquid vehicle for pharmaceutical compositions
ES358505A1 (en) Sustained Release Tablet Coating.
IL35490A0 (en) New penicillanic acid derivatives,their preparation and pharmaceutical compositions containing them
GB1442159A (en) Pharmaceutical compositions containing paracetamol
GB1547562A (en) Guns eg for use in the administration of drugs or medicines to animals
IL49668A0 (en) Stable solutions of ergot alkaloids,their preparation and pharmaceutical compositions comprising them
GB769517A (en) Analgesic compositions
IL43927A0 (en) Lysino-calcium chloride and acid addition salts thereof,their preparation and pharmaceutical compositions containing them
GB1300419A (en) New morphinone derivatives and their preparation
IE34648B1 (en) Pharmaceutical compositions and a process for the manufacture thereof
GB894609A (en) Tannates of morphine alkaloids
IL34468A0 (en) Acid addition salts of indenopyridine derivatives,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PS Patent sealed
PLNP Patent lapsed through nonpayment of renewal fees